<DOC>
	<DOCNO>NCT01790217</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety Tarceva ( erlotinib ) first-line therapy patient locally advance metastatic EGFR mutation-positive non-small cell lung cancer . Eligible patient , treat physician decide initiate treatment Tarceva accord local label follow 18 month .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) First Line Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer ( GERTAC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advance metastatic EGFR mutationpositive nonsmall cell lung cancer Patients treat physician decide initiate firstline therapy Tarceva accordance Summary Product Characteristics local guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>